

I. AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (currently amended) A method for ~~the~~-inhibiting the loss of visual acuity associated with AMD, which comprises, administering to a patient from 3 mg – 30 mg of the compound anecortave acetate or its corresponding alcohol, wherein said administering is by a method selected from the group consisting of posterior juxtascleral injection, juxtascleral implant, intravitreal injection, or implant.

Claim 2 (original) The method of claim 1, wherein the compound is administered as a juxtascleral depot.

Claim 3 (canceled)

Claim 4 (previously presented) The method of claim 2, wherein the depot comprises 15 mg of compound.

Claim 5 (previously presented) A method for maintaining visual acuity in a person suffering from AMD, which comprises administering to a patient from 3 mg – 30 mg of the compound anecortave acetate or its corresponding alcohol, wherein said administering is by a method selected from the group consisting of posterior juxtascleral injection, juxtascleral implant, intravitreal injection, or implant.

Claim 6 (original) The method of claim 5, wherein the compound is administered as a juxtascleral depot.

Claim 7 (canceled)

Claim 8 (previously presented) The method of claim 6, wherein the depot comprises 15 mg of compound.

Claim 9 (previously presented) A method for the inhibition of lesion growth associated with AMD, which comprises administering to a patient from 3 mg – 30 mg of the compound anecortave acetate or its corresponding alcohol, wherein said administering is by a method selected from the group consisting of posterior juxtascleral injection, juxtascleral implant, intravitreal injection, or implant.

Claim 10 (original) The method of claim 9, wherein the compound is administered as a juxtascleral depot.

Claim 11 (canceled)

Claim 12 (previously presented) The method of claim 10, wherein the depot comprises 15 mg of compound.

Claim 13 (previously presented) The method of any one of claims 1, 5, or 9, wherein the compound is administered in a juxtascleral implant.

Claim 14 (previously presented) A method for inhibiting blood vessel growth associated with AMD, said method comprising administering to a patient from 3 mg – 30 mg of the compound anecortave acetate or its accompanying alcohol, wherein the administering is by juxtascleral injection, intravitreal injection, juxtascleral implant, or other implant.

Claim 15 (canceled)

Claim 16 (previously presented) The method of claim 14, wherein the amount of compound administered is 15 mg.

Claim 17 (previously presented) The method of claim 9, wherein the lesion is a predominantly classic subfoveal lesion.

Claim 18 (previously presented) The method of claim 9, wherein the lesion is a minimally classic lesion.